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Abstract
Background: Glioma is a heterogeneous, invasive primary brain tumor with a wide range of patient survival and a lack
of reliable prognostic biomarkers. Human telomerase reverse transcriptase (hTERT) has been reported in the presence
of multiple transcripts in various tumor systems. The biological function and precise regulatory mechanisms of hTERT
transcripts remain uncertain.
Methods: Alternative splicing of hTERT and telomerase activity were examined in 96 glioma specimens, including 38
glioblastomas (GBMs), 23 oligodendrogliomas (ODMs), and 35 oligoastrocytomas (OAMs). The correlation between
telomerase activity or hTERT transcripts and patient clinical characteristics was investigated. We examined the regulation
of alternative splicing of hTERT and telomerase activity by G-quadruplex stabilizer CX-5461 in GBM cells. The biological
effects of CX-5461 on GBM cell lines, including inhibition of cell proliferation, effects on cell cycle/apoptosis, and
telomere DNA damage were further explored.
Results: The β splicing was verified in human gliomas and hTERT+β was significantly correlated with higher telomerase
activity, higher KPS, larger tumor size, and higher tumor grades. Meanwhile, glioma patients lacking hTERT+β expression
or telomerase activity showed a significant survival benefit. Notably, CX-5461 altered hTERT splicing patterns, leading to
an increase of hTERT-β transcript and a decrease of hTERT+β transcript expression, which inhibits telomerase
activity. In addition, CX-5461 had cytotoxic effects on GBM cells and caused telomere DNA damage response,
induced G2/M arrest and apoptosis.
Conclusions: The hTERT+β is verified to be correlated with clinical parameters in gliomas, and could serve as a
prognostic marker or possibly therapeutic target for gliomas. CX-5461 can regulate the splicing pattern of
hTERT, inhibit telomerase activity, and kill GBM cells.
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Background
Telomeres are essential to maintain the stability of
chromosome ends, and two telomere maintenance
mechanisms are known [1]. The most frequent one is
telomerase, a specific enzyme that adds telomeric
repeats to chromosomes and lengthens telomeres. Most
cancer cells escape telomere shortening by activating the
telomerase, which leads to unlimited proliferation
capacity and immortalization. About 10% of cancer cells
do not show telomerase activity, but instead maintain
telomere length by the recombination-based alternative
lengthening of telomeres (ALT) mechanism [1–3].
Telomerase is a ribonucleoprotein with two key sub-
units: human telomerase RNA (hTR), which acts as a
transcription template [4, 5], and human telomerase
reverse transcriptase (hTERT), whose expression controls
enzymatic activity [6]. In humans, the hTR transcript is
constitutively produced, whereas the production of
hTERT is highly regulated at both the transcriptional
levels and post-transcriptional levels [7–9]. A number of
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studies have shown the presence of different transcripts of
hTERT, including three deletions and four insertions,
which may affect telomerase activity and biological func-
tions [10–12]. Further evidence has accumulated that only
a full-length hTERT (hTERT-FL) transcript is associated
with telomerase activity. Four insertions and the β and γ
deletion result in nonfunctional proteins whereas the α
deletion is a dominant negative inhibitor of telomerase
activity [13, 14]. The most widely studied variants involve
splicing at two main sites: the α splice site in exon 6,
which produces a 36-bp in frame deletion within the con-
served reverse transcript motif A; and the β splice site in
exon 7 and exon 8, which results in a 182-bp deletion and
nonsense mutation that truncates the protein [15–18]
(Fig. 1a). Alternative splicing of hTERT mRNA has been
shown to contribute to the regulation of telomerase activ-
ity and might be used as an additional prognostic marker
in certain types of malignancies.
Gliomas are the most frequent primary brain tumors,
characterized by high aggressiveness based on local
diffuse infiltration, and always remain poor prognosis
[19]. Gliomas show marked heterogeneity at the micro-
scopic and molecular levels, which are mainly reflected
in the clinical course of individual changes. However,
only a few reliable biomarkers currently exist to predict
the course of disease or outcome of glioma patients [20].
Studies show that high telomerase activity or hTERT
promoter mutations are prognostic markers for human
brain tumors [21–25]. In association with tumor histo-
pathology and clinical parameters, expression of hTERT
transcripts may serve as diagnostic or prognostic bio-
markers for certain cancer patients [17, 18, 26].
Telomerase is an attractive target for cancer treatment,
and the regulation of hTERT alternative splicing tran-
script patterns would be one therapeutic strategy [27].
Telomerase activity decreases with down-regulation of
active hTERT mRNA transcription. Previous studies
have shown that transforming growth factor-β (TGF-
β) and antisense oligonucleotides treatments inhibit
telomerase activity by altering the splicing patterns of
hTERT pre-mRNA [28, 29]. Another study reported a
G-quadruplex stabilizer called 12,459 that converts
hTERT-FL to hTERT-β transcript in A549 cells [30].
G-quadruplex structures have been extensively studied
in the telomeric single-stranded overhang or c-myc
gene promotor sequence, and hTERT intron 6 was
reported to have two G-rich sequences able to form
G-quadruplex, which may affect β splicing [30–32].
Similarly, CX-5461, as an rDNA transcription inhibi-
tor currently in phase I trials for malignancies, is re-
ported to strongly bind and stabilize G-quadruplex
and induce DNA damage in vitro [33–35]. In addition,
Fig. 1 hTERT alternative splice variant patterns in human gliomas and cell lines. a Two main alternative splicing sites: the α splice site in exon 6, which
produces a 36-bp in frame deletion; and the β splice site in exon 7 and exon 8, which results in a 182-bp deletion and nonsense mutation that truncates
the protein. hTERT variant patterns of cell lines (b) and human gliomas including 38 GBMs (c), 24 ODMs (d) and 35 OAMs (e) were investigated by RT-PCR
(Only a representative portion of the total analyzed samples was shown in the gels). Two hTERT alternative splice variants (hTERT+β and hTERT–β) were
detected in subsets of the tumors and cell lines. Thirty-three of 38 (86.8%) GBMs, 17 of 24 (73.9%) ODMs and 15 of 35 (42.9%) OAMs exhibited hTERT+β
transcript, and the remaining 31 cases only exhibited hTERT–β transcript. Accordingly, cases with hTERT +β transcript were consistent with the expression
of hTERT-FL transcript
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other G-quadruplex stabilizers, BRACO-19 and TMPyP4,
also have the potential to regulate alternative splicing vari-
ants of hTERT [36, 37].
In this study, we investigated hTERT alternative splice
variant patterns of human gliomas and its correlation
with telomere activity. Then, we focused on the correl-
ation between telomerase activity or hTERT-FL mRNA
and patient clinical characteristics.
We examined the regulation of alternative splicing of
hTERT and telomerase activity by G-quadruplex stabilizer
CX-5461 in GBM cells. The biological effects of CX-5461
on GBM cell lines, including inhibition of cell prolifera-
tion, effects on cell cycle/apoptosis, and telomere DNA
damage were further explored.
Methods
Cell lines and cell culture
Six tumor cell lines, T98G (human glioblastoma), U251
(human glioblastoma), SH-SY5Y (human neuroblastoma),
Hela (human cervical cancer), GM847 (ALT+, TA-, hu-
man fibroblast), C6 (rat glioma), and one normal cell line
HEB (Human normal astrocyte) were obtained from the
Shanghai Institute of Cell Biology at the Chinese Academy
of Sciences (Shanghai, China). The cells were grown in
Dulbecco’s modified eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) (Biowest,
South America Origin) and antibiotics (100 units/mL
penicillin and streptomycin) in a humidified incubator
maintained at 37 °C with 95% air and 5% CO2. Cells at
logarithmically growing phases were harvested for hTERT
mRNA and telomerase activity analyses. Hela cell line was
regarded as positive control for telomerase activity
analyses and GM847 (ALT+) cell line was regarded as
negative control for telomerase activity analyses. CX-
5461 compound was purchased from Selleck Chemi-
cals. TMPyP4 and BRACO-19 were purchased from
R&D Systems.
Patients and tissue specimens
The cohort consisted of 96 patients and diagnosed
between 2012 and 2014 from the first hospital of Jilin
University. All patients with glioma and corresponding
clinical information were obtained with consent and the
project was approved by the ethics committee of the
First Hospital of Jilin University. The details concerning
age, gender, KPS, tumor size (diameter), histopathology
and WHO grade, and extent of resection were retro-
spectively summarized in Table 1. Samples included 38
Table 1 Characteristics of glioma patients according to TA and hTERT transcript
Characteristics n patients (%) TA, n patients
(%)
P hTERT, n patients
(%)
P









Male 51 (53.1) 36 (70.6) 15 (29.4) 35 (68.6) 16 (31.4)
female 45 (46.9) 31 (68.9) 14 (31.1) 30 (66.7) 15 (33.3)
Age 0.007* 0.029*
<50 52 (54.2) 30 (57.7) 22 (42.3) 30 (57.7) 22 (42.3)
≥ 50 44 (45.8) 37 (84.1) 7 (15.9) 35 (79.5) 9 (20.5)
KPS 0.012* 0.015*
<75 57 (59.4) 34 (59.6) 23 (40.4) 33 (57.9) 24 (42.1)
≥ 75 39 (40.6) 33 (84.6) 6 (15.4) 32 (82.1) 7 (17.9)
Tumor size (cm) 0.008* 0.002*
<6 49 (51) 28 (57.1) 21 (42.9) 26 (53.1) 23 (46.9)
≥ 6 47 (49) 39 (83) 8 (17) 39 (83) 8 (17)
Histopathology and WHO grade 0.001* 0.001*
GBMs (IV) 38 (39.6) 34 (89.5) 4 (10.5) 33 (86.8) 5 (13.2)
ODMs (III) 23 (24) 17 (73.9) 6 (26.1) 17 (73.9) 6 (26.1)
OAMs (III, II) 35 (36.4) 16 (45.7) 19 (54.2) 15 (42.9) 20 (57.1)
Extent of resection 0.082 0.334
GTR 71 (74) 46 (64.8) 25 (35.2) 46 (64.8) 25 (35.2)
STR 25 (26) 21 (84) 4 (16) 19 (76) 6 (24)
*P-values indicating significance; KPS Karnofsky Performance Score, GTR Gross-total Resection; STR Subtotal Resection
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glioblastomas (GBMs, Grade IV), 23 oligodendrogli-
omas (ODMs, Grade II or III), and 35 oligoastrocyto-
mas (OAMs, Grade II or III). After surgery, samples
were snap frozen in liquid nitrogen and stored at −
80 °C until use.
RNA extraction, reverse transcription, PCR
Total cellular RNA in the cell lines and tissue specimens
were extracted using the EasyPure RNA kit (TRANSGEN
BIOTECH). Reverse transcription was performed with
1 μg of total RNA and oligo (dT) primers by TransScript
One-step gDNA Removal and cDNA Synthesis (TRANS-
GEN BIOTECH). The relative gene expression levels of
hTERT alternative splice variants were analyzed by PCR
using primers designed according to GenBank accession
no. AF015950. The PCR primer sequences specific for all
the variants of hTERT (hTERT-All) mRNA were 5’-CG
GAAGAGTGTCTGGAGCAA-3′ (1784–1803, forward)
and 5’-GGATGAAGCGGAGTCTGGA -3′ (1928–1910,
reverse). The PCR primer sequences specific for hTERT-
FL transcript were 5’-TGTACTTTGTCAAGGTGGATG
TG-3′ (2172–2194, forward) and 5’-GTACGGCTGGAG
GTCTGTCAAG-3′ (2371–2350, reverse). The primers set
for hTERT α or β splicing transcript variant were
5’-CCGCCTGAGCTGTACTTTGTC-3′ (2162–2183, for-
ward) and 5’-CAGAGCAGCGTGGAGAGGAT-3′ (258
0–2560, reverse), which produced four possible products,
α + β + (418 bp), α + β– (236 bp), α–β + (382 bp), and
α–β– (200 bp), respectively. All PCR was performed in
50 μL of reaction mixture using 2 μL of the cDNA and Ex
Taq DNA polymerase (TaKaRa) by incubation at 94 °C
for 2 min, followed by 35 amplification cycles of 94 °C
for 30 s, specific annealing temperature for 45 s, and
72 °C for 60 s, and a final extension at 72 °C for 5 min.
Annealing temperature was 58 °C for hTERT 1784/
1928, 63 °C for hTERT 2172/2371, and 62 °C for
hTERT 2162/2580. Amplified products were electro-
phoresed on 2% agarose gels with GelStar Nucleic Acid
Gel Stain (LONZA) or electrophoresed on a 12% non-
denaturing polyacrylamide gel staining with 0.2%
AgNO3. Images were photographed using a UVP gel
documentation system (Ultraviolet Products, Upland,
CA, USA). The expression of β-Actin or β2m was
served as an internal control.
Telomere repeat amplification protocol (TRAP) assay
For the assessment of telomerase activity (TA), a modi-
fied version of the telomere repeat amplification proto-
col (TRAP) assay was applied. Briefly, telomerase was
prepared from extracts of 2 × 105 exponentially growing
cells or 40 mg tumor samples by lysing for 30 min on
ice in 200 μL TRAPEZE® 1 × CHAPS Lysis Buffer
(Millipore s7750). The lysate was then centrifuged at
12,000 g for 20 min at 4 °C, and the supernatant was
collected, frozen in liquid nitrogen and stored at − 80 °C
for use. Total cellular protein was then determined, we
assayed 1 μg of protein extract in a 40 μL reaction
mixture that contained 10 × TRAP buffer (4.0 μL),
bovine serum albumin (BSA, 0.5 μL, 0.05 μg sample− 1),
dNTPs mix (2.0 μL, 2.5 mM, TaKaRa), TS primer (1.
0 μL, 100 ng μL − 1), and DEPC (diethyl pyrocarbonate)-
treated water (31.5 μL). Negative control involved
incubating 1.0 μL of cell lysate at 94 °C for 10 min prior
to primer extension. The Hela cell line (American Type
Culture Collection) served as a positive control. Then
the mixtures were involved incubation for 45 min at 30 °
C for the initial elongation step, followed by 94 °C for
5 min. The elongated products were then subjected to
PCR amplification. The PCR master mix consisted of
10 × TRAP buffer (1.0 μL), dNTPs mix (4.0 μL, 2.5 mM,
TaKaRa), TS primer (1.0 μL,100 ng μL − 1), primer mix
(2.0 μL; ACX reverse primer 100 ng μL − 1; NT primer
100 ng μL − 1, and TSNT internal control primer 1×
10− 7 μM), Ex Taq polymerase (0.5 μL, 5 U μL -1),
DEPC water (1.5 μL) and elongated products (40 μL).
The mixture was amplified at 94 °C for 2 min, followed
by 35 cycles of PCR reaction (94 °C for 30 s, 52 °C for
30 s, and 72 °C for 60 s) on an AMPLITRON®
Thermolyne (Alpha Multiservices, Inc). Amplified
products were visualized on a 12% nondenaturing
polyacrylamide gel, after electrophoresis and staining
with 0.2% AgNO3. Images were photographed using a
UVP gel documentation system (Ultraviolet Products,
Upland, CA, USA). Telomerase activity was assessed by
determining the ratio of the entire telomerase ladder to
that of the internal control, using Lab works 4.5 image
analysis software.
Western blot
Cells in the log growth phase were seeded on 100 mm
dishes (Falcon) and allowed to adhere overnight prior to
treatment. After treatment for 48 h, cells were collected
and lysed in RIPA buffer, and centrifuged at 12,000×g
for 20 min. The total protein concentration was quanti-
fied with a bicinchoninic acid assay kit. Equal amounts
of proteins were loaded onto SDS-PAGE gels, and sepa-
rated proteins were transferred to PVDF membranes.
After blocking with 5% skim milk, the membranes
were incubated with primary antibodies against hTERT
(Abcam, ab32020, diluted 1:1000), cyclin D1 (Cell Sig-
naling Technology, #2978, diluted 1:1000), p53 (Cell
Signaling Technology, #2527, diluted 1:1000), p16
(Abcam, ab81278, diluted 1:2000), γ-H2AX (Abcam,
ab81299, diluted 1:5000), 53BP1 (Abcam, ab175933,
diluted 1:5000), p-ATM (Abcam, ab81292, diluted 1:
5000), Bcl-2 (Cell Signaling Technology, #4223, diluted
1:1000), caspase-3 (Cell Signaling Technology, #9662,
diluted 1:1000) or Bax (Cell Signaling Technology,
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#5023, diluted 1:1000) and a monoclonal antibody
against β-actin (Cell Signaling Technology, #4970,
diluted 1:1000) was used as a protein endogenous con-
trol. The membranes were washed three times with
PBS-T (0.1% [v/v] Triton-X 100) buffer for 0.5 h, then
incubated with goat anti-rabbit IgG (H + L) poly-HRP
secondary antibody (Thermo Fisher Scientific, #32260,
diluted 1:10000) for 2 h. After washing with the PBS-
T buffer again, membranes were scanned with the
Odyssey Infrared Imaging System (LI-COR).
Cell viability assay
The cytotoxicity of CX-5461 to GBM cells was deter-
mined by the MTT assay. T98G, U251, C6 and HEB
cells were seeded in 96-well plate and exposed to
CX-5461 at concentration of 0, 0.04, 0.2, 1, 5, 25 μM for
48 h. 20 μl MTT (5 mg/ml) (Promega, Shanghai, China)
was added to each well and incubated for 4 h. Dimethyl
Sulphoxide (DMSO) was added to the well after discard-
ing the supernatant. Then, the plate was shaken for
3 min. The absorbance was measured at 570 nm wave-
length using a Microplate Reader (Bio-Rad, Hercules,
CA, USA).
Colony formation assay
Cells in the log growth phase were seeded in 6-well
plates at a density of 1 × 103 cells per well and allowed
to attach to the plate overnight prior to treatment. Cells
were then incubated with CX-5461 at the indicated con-
centrations for 8 days. Then, they were fixed with 4%
formaldehyde and stained with crystal violet. The num-
ber of colonies with at least 50 cells was counted under
a microscope.
Flow cytometric assays
Briefly, cells were seeded in 6-well plates at a density of
2 × 105 cells per well. After treatment with CX-5461,
cells were harvested with the accutase detachment solu-
tion (Sigma Aldrich, USA). For the detection of cell
cycle, cells were fixed in 70% ethanol for 12 h at − 20 °C
after collection, then washed twice with PBS, and incu-
bated with 1 g/ml propidium iodide (PI) and RNase for
30 min. Apoptotic cells were quantified with an
annexin-V-fluorescein isothiocyanate (FITC)/propidium
iodide (PI) apoptosis detection kit (BD) according to the
manufacturer’s instructions. Then the stained cells were
analyzed with a flow cytometer. We used the FACSDiva
Version 6.2 to calculate the numbers of viable cells
(annexin-V–/PI–), early apoptotic cells (annexin-V
+/PI–), and late apoptotic cells (annexin-V+/PI+).
Statistical analysis
All experiments were performed in triplicate, unless
otherwise noted. The analyzed results are expressed as
the mean ± SD. Groups were compared with the un-
paired Student’s t-tests. Survival curves were illustrated
by Kaplan-Meier plots, and significance was calculated
by log-rank test. Characteristics according to TA or
hTERT transcript were evaluated by χ2 test. All analyses
were performed with SPSS software version 21.0 for
Windows or Graph Pad Prism 7.0.
Results
hTERT alternative splice variant patterns in human
gliomas and cell lines
We investigated hTERT transcript patterns by RT-PCR,
and found that hTERT-All expressed in all human
glioma tissues and cell lines (Fig. 1b-e). Then, we used
another pair of primers specific to hTERT-FL mRNA to
perform PCR analysis on the same batch of cDNA.
While hTERT-FL mRNA was detected in about 86.8%
GBMs, 73.9% ODMs, and 42.9% OAMs (Fig. 1c-e).
Considering the existence of different alternative splice
variants, the expression of hTERT was further character-
ized. Two hTERT alternative splice variants (hTERT+β
and hTERT–β) were detected in subsets of the gliomas,
as illustrated for representative cases (Fig. 1c-e). How-
ever, α splice variant was not detected in any human
glioma tissues or GBM cell lines. Thirty-three of the 38
GBM cases, 17 of the 23 ODMs and 15 of the 35 OAMs
exhibited hTERT+β transcript, and the remaining 31
cases only exhibited hTERT–β transcript. Accordingly,
cases with hTERT+β transcript were consistent with the
expression of hTERT-FL transcript. When hTERT+β
transcript expression was correlated with clinical
variables, its presence was found to be significantly
associated with age, KPS, tumor size, and WHO
tumor grade (Table 1). These findings indicate that
hTERT+β transcript is associated with more aggres-
sive growth of gliomas.
Concomitant of telomerase activity and hTERT+β
transcript in human gliomas and cell lines
Relative telomerase activity of 96 glioma samples and
cell lines was detected by TRAP assay. Thirty-four of 38
(89.5%) GBMs, 17 of 23 (73.9%) ODMs, and 16 of 35
(45.7%) OAMs and GBM cell lines exhibited high TA
(Fig. 2a-d), which was consistent with the expression of
hTERT-FL or hTERT+β transcript (Fig. 2e). We found
that TA was not related to the patient’s gender or extent
of resection. However, TA was significantly correlated
with age, tumor size, KPS, and WHO grades (Table 1).
Thirty of 52 (57.7%) patients with age < 50 were positive
for TA, while 37 of 44 (84.1%) patients with age ≥ 50
were positive. Twenty-eight of 49 (57.1%) patients with
glioma size < 6 cm were positive for TA, while 39 of
47(83%) with glioma size ≥6 cm were positive. And,
thirty-four of 57 (59.6%) patients with KPS < 75 were
Li et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:78 Page 5 of 13
positive for TA, while 33 of 39 (84.6%) patients with
KPS ≥ 75 were positive. Expression of hTERT+β tran-
script was positively correlated with elevated telomerase
activity, which may indicate deterioration of the disease.
Telomerase status and hTERT+β transcript predict
survival in human gliomas
To evaluate the effects of telomerase activation on
disease progression, after 36 months of follow-up, we
correlated the expression of hTERT+β (hTERT-FL) or
TA with the survival time of glioma patients. Kaplan–
Meier estimates revealed a significant survival benefit
for patients lacking hTERT+β or TA in different WHO
grade gliomas including 38 GBMs, 23 ODMs and 35
OAMs (Fig. 3a-c). Hence, we find a correlation be-
tween clinical outcome and hTERT-FL transcript or
high TA in glioma patients.
CX-5461 could alter hTERT alternative splicing in GBM
cells
To explore the regulation of hTERT alternative splicing,
the GBM cells were exposed to 3 different G-quadruplex
stabilizers. The expression of hTERT transcripts were
investigated by RT-PCR. CX-5461 significantly altered its
splicing patterns resulting in a dramatic drop of hTERT
+β transcript in T98G and U251 cells (Fig. 4a, b). While
the other two G-quadruplex stabilizers, TMPyP4 and
BRACO-19 (1 mM, 48 h) did not significantly alter its
splicing patterns. The expression of alternative splicing
of hTERT was detected after GBM cells were exposed to
different concentrations of CX-5461 (0, 0.2, 1, 5 μM) for
48 h. As predicted, CX-5461 could lead to a decrease of
hTERT+β transcript and to an increase of hTERT-β in a
dose-dependent manner both in T98G and U251 cells
(Fig. 4c, d). Similarly, CX-5461 could lead to a significant
decrease of hTERT-FL in a dose-dependent manner and
had no effect on hTERT-All (Fig. 4e, f ). Down-regulation
of this active hTERT transcript may explain short-term
inhibition of telomerase activity.
CX-5461 weakly decreased hTERT protein expression but
effectively inhibited telomerase activity in GBM cells
To better understand the potential mechanisms of CX-
5461 mediated anti-telomerase activity, we performed
western blot using hTERT antibody. The telomerase activ-
ity inhibition of CX-5461 was investigated by traditional
Fig. 2 Relative telomerase activity in human gliomas and cell lines. a Telomerase activity was detected by TRAP assay, and all four cell lines exhibited
high TA. Thirty-four of 38 (89.5%) GBMs (b), 17 of 23 (73.9%) ODMs (c), and 16 of 35 (35.7%) OAMs (d) exhibited high TA. e The high telomerase activity
of human gliomas was significantly consistent with the expression of hTERT+β transcript
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TRAP assay in T98G and U251 cells. GBM cells were
treated with CX-5461 for 48 h at concentrations ranging
from 0 to 5 μM. The results showed that CX-5461 only
weakly down-regulated hTERT protein expression in
T98G and U251 cells (Fig. 5a, b). In contrast, signifi-
cant dose-dependent telomerase activity inhibition was
observed in GBM cells after treatment with CX-5461
(Fig. 5c, d). At 5 μM drug concentration, telomerase
activity was almost completely inhibited. These results
indicate that hTERT-β could be translated into a trun-
cated hTERT protein without telomerase activity.
CX-5461 selectively inhibited GBM cell proliferation and
induced G2/M cell cycle arrest
Significant dose-dependent growth inhibition induced
by CX-5461 was observed in T98G, U251 and C6 cells
(Fig. 6a). After exposure to CX-5461 (1 μM) for 48 h,
significant cell inhibitory effects were found in GBM
cells but not in human normal astrocyte HEB cells
(Fig. 6a). Moreover, compared to the control group,
colony formation was inhibited in GBM cells after
8 days of incubation with CX-5461 (Fig. 6b). After
treatment with CX-5461, GBM cells were collected
and stained with propidium iodide (PI), and then DNA
content was determined by flow cytometry. As shown,
G2/M cell cycle arrest was induced by CX-5461 in
T98G and U251 cells (Fig. 6c). Furthermore, western
blot results showed that CX-5461 increased the pro-
tein levels of p53 and p16, and decreased the protein
levels of cyclin D1 both in T98G and U251 cells
(Fig. 6d). The above results indicate that CX-5461
can selectively inhibit cell proliferation and interfere
with the cell cycle progression of GBM cells with
the cell cycle progression of GBM cells.
Short-term apoptosis was evoked by CX-5461-induced
DNA damage response
To determine the effect of CX-5461 on cell apoptosis
during short-term treatment, we exposed T98G and
U251 to CX-5461 in a concentration range of 0–5 μM
Fig. 3 Telomerase-associated parameters compared with overall survival. Kaplan–Meier estimates revealed a significant survival benefit for glioma
patients lacking hTERT+β (Right) or TA (Left) in different WHO grade gliomas including 38 GBMs (a), 23 ODMs (b) and 35 OAMs (c)
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and performed annexin V assay to assess percentage of
apoptotic cells. As shown (Fig. 7a, b), CX-5461 could
induce apoptosis in a dose-dependent manner in T98G
and U251 cells. Next, we investigated whether the apop-
tosis induced by CX-5461 is related to the generation of
DNA damage response. As predicted, treatment with
CX-5461 for 48 h induced a strong increase of γ-H2AX,
53BP1, and p-ATM, which are hallmarks of DNA
double-strand break response [38, 39] (Fig. 7c).
Moreover, we examined the changes in apoptotic
related proteins after treated with CX-5461 for 48 h.
Compared with the control group, the expression of
Bcl-2 significantly decreased, while the activity of
cleaved caspase-3 and Bax significantly increased.
(Fig. 7d). Based on these results, we demonstrated
that apoptosis induced by CX-5461 is associated with
the generation of DNA damage response. CX-5461
can not only inhibit telomerase, but also triggers a
series of telomere-related cellular events to against
GBM cells.
Discussion
Numerous studies in the past three decades revealed that
telomerase activation is one of the most important mecha-
nisms in carcinogenesis [21, 40, 41]. The regulation of
telomerase activity is fairly complicated, including various
levels such as transcription, post-transcription, post-
translation and sub-cellular localization [7]. Recent studies
revealed an important role for alternative splicing, a post-
transcriptional mechanism of hTERT mRNA in the regu-
lation of telomerase activity [11, 12, 26, 42]. It has been
established that there are at least five different alternative
splicing sites of hTERT, among which only hTERT-FL
mRNA encodes a functional hTERT protein essential for
the active enzyme [10–12]. The frequent finding of
hTERT transcripts in various tumor types indicates that a
Fig. 4 CX-5461 altered hTERT alternative splicing in GBM cells. a The expression of hTERT transcripts were investigated by RT-PCR analysis. CX-5461 (1 μM,
48 h) markedly altered its splicing patterns, leading to a sharp decrease of hTERT+β transcript in T98G and U251 cells. While TMPyP4 and BRACO-19, two
other G-quadruplex stabilizers, did not significantly alter its splicing patterns. b The histogram showed transcripts expression levels relative to control. c
CX-5461 could lead to a decrease of hTERT+β transcript and to an increase of hTERT-β in a dose-dependent manner in T98G and U251 cells. d The
histogram showed transcripts expression levels relative to control. e CX-5461 could lead to a significant decrease of hTERT-FL in a dose-dependent manner
and had no effect on hTERT-All. f The histogram showed transcripts expression levels relative to control. *P< 0.05, **P< 0.01 vs. control group
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splicing control of hTERT mRNA for telomerase inactiva-
tion may occur in multiple human tumors.
The present data clearly demonstrated that hTERT-FL
mRNA is detected in about 86.8% GBMs, 73.9% ODMs,
and 42.9% OAMs. Especially, two hTERT alternative splice
variants (hTERT+β and hTERT–β) were detected in
human glioma tissues and GBM cell lines. Accordingly,
cases with hTERT+β transcript were consistent with the
expression of hTERT-FL transcript. Moreover, 89% GBMs,
71% ODMs and 46% OAMs exhibited high TA, which was
consistent with the expression of hTERT-FL or hTERT+β
transcript. However, most studies simply measured
hTERT-All transcript or focused on telomerase activity,
which greatly depends on assay conditions and sample
preservation [16, 19, 43]. We suggest that analysis of
hTERT-FL mRNA and telomerase activity should be com-
pleted in future related studies.
The clinical outcomes of patients with gliomas show
great differences. Although extensive efforts have been
made to determine the exact biomarkers for gliomas,
more reliable prognostic predictors are required [19,
20]. It has been shown that telomerase activity and
hTERT-FL expression are powerful predictors for neu-
roblastomas [18, 44] and certain types of malignancies
[15, 17, 42, 45, 46]. When hTERT+β transcript expres-
sion or high TA was correlated with the clinical vari-
ables of the patients, its presence is found to be
significantly correlated with age ≥ 50, KPS ≥ 75, tumor
size ≥6 cm, and higher tumor WHO grades. Survival
analysis showed a significant survival benefit for pa-
tients lacking hTERT+β or TA in different WHO
grade gliomas. Hence, our results demonstrate a cor-
relation between clinical outcome and hTERT-FL tran-
script or higher TA. It is interesting to define whether
these two variables will independently add prognostic
information in larger cohorts of patients with gliomas.
In particular, grade II and III telomerase-negative
ODMs and OAMs are frequently ALT-positive [47,
48]. Unfortunately, we did not detect ALT in glioma
samples, which is a disadvantage of this study. For
telomerase-negative patients, ALT may also have some
effect on prognosis.
Although hTERT alternative transcripts have been de-
scribed in a number of malignant tumors, little is known
about the causes of splice variants and how they are
regulated [27]. A previous study showed that TGF-β1
converts splicing from hTERT-FL to hTERT–β transcript
in epidermal cells [29]. The antisense oligonucleotides
were reported to change the splicing patterns of hTERT
pre-mRNA to induce telomerase inhibition and cell
growth decline in human prostate cancer cells [28].
Another study reported a G-quadruplex stabilizer named
12,459 switching splicing from hTERT-FL to hTERT–β
transcript in A549 cells [30]. G-quadruplex structures
have been extensively studied in the telomeric single-
stranded overhang or c-myc gene promotor sequence,
and hTERT intron 6 was reported to have two G-rich
sequences able to form G-quadruplex, which may affect
β splicing [30–32]. Similarly, CX-5461 also promotes the
stabilization of these G-quadruplexes, as demonstrated
by specific PCR-stop assay [35]. Our current data indicate
that CX-5461 can modify alternative splicing of hTERT,
convert hTERT-FL to hTERT-β transcript, and hardly
affect hTERT-All transcription in T98G and U251 cells. A
possible explanation for the hTERT-β splicing would be
that these G-rich sequences of intron 6 bind to a splicing
factor involved in the negative control of hTERT-β alter-
native splicing. In that case, the stabilization of this region
Fig. 5 CX-5461 weakly decreased hTERT protein expression, but
effectively inhibited telomerase activity in GBM cells. a The hTERT
protein was detected both in T98G and U251 cells by immunoblotting
after treatment with CX-5461 for 48 h, and β-actin was used as loading
control. b The histogram showed hTERT protein expression levels relative
to control. P>0.05 vs. control group. c After treatment with CX-5461 for
48 h, the telomerase activity of GBM cells was detected by TRAP assay. d
The histogram showed a significant dose-dependent telomerase activity
inhibition of CX-5461 in GBM cells. *P< 0.05, **P< 0.01
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into G-quadruplex by CX-5461 would impair the binding
of this factor and would provoke hTERT-β alternative
splicing.
We also demonstrated that CX-5461 could effectively
inhibit telomerase activity independent of hTERT pro-
tein expression in GBM cells. It is consistent with the
results of a study in which TERT-β transcript can be
translated into a truncated hTERT protein without
telomerase activity [49]. The effect of CX-5461 resulted
in downregulation of hTERT+β transcript and increase
in hTERT-β transcript, explaining the downregulation of
hTERT-FL and telomerase activity. A detailed analysis of
the action of CX-5461 aiming to reconstitute the splicing
of hTERT would be necessary to understand the bio-
logical effect of this stabilizer.
CX-546 was reported to have biological efficacy in
multiple studies [33–35]. In this study, we demonstrated
that CX-5461 could selectively inhibit GBM cell prolifer-
ation and induce G2/M cell cycle arrest. This result is
consistent with the periodic arrest induced by most telo-
mere G-quadruplex ligands, and there is evidence that
the response of telomere injury is G1 or G2 cell cycle
Fig. 6 CX-5461 selectively inhibited cell proliferation and induced G2/M cell cycle arrest. a T98G and U251 cells exhibited significant inhibition of
cell proliferation when 0.04–25 μM CX-5461 was used. C6 cells showed a modest cytotoxic effect, while human normal astrocyte HEB cells showed only
a weak cytotoxic effect. b Representative images of colony formation and analysis of the colony numbers were observed in T98G and U251 cells after
treatment with CX-5461 at indicated concentrations for 8 days. c G2/M cell cycle arrest was induced by CX-5461 in T98G and U251 cells. After treatment
with CX-5461, cells were collected and stained with propidium iodide (PI), and then DNA content was determined by flow cytometry. d The cell cycle
related proteins cyclin D1, p53, p16 were detected by immunoblotting after treatment with CX-5461 for 48 h, and β-actin was used as loading control.
*P < 0.05, **P< 0.01 vs. control group
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arrest [37]. Apoptosis in cancer cells induced by DNA
damage response has been described as one of the char-
acteristics of G-quadruplex ligands, and our previous
study has demonstrated it [34–37]. This study shows
that short-term apoptosis induced by CX-5461 is associ-
ated with the generation of DNA damage response. CX-
5461 can not only inhibit telomerase activity, but also
triggers a series of telomere-related cellular events to
against GBM cells. Unlike other G-quadruplex ligands,
CX-5461 may contribute to inhibition of telomerase
activity through two different mechanisms. In addition
to the stabilization of G-quadruplex in telomeric over-
hang repeats as reported, CX-5461 could also induce
downregulation of active hTERT transcript to inhibit
telomerase activity.
Conclusions
In conclusion, our study clarifies the patterns of alter-
native splice variant of hTERT and highlights the strik-
ing correlation between hTERT+β expression and
telomerase activity in gliomas. The alternative splicing
of hTERT is verified to be correlated with histopatho-
logical and clinical parameters of gliomas, and could
serve as a prognostic marker or possibly therapeutic
target for glioma patients. However, the exactly regu-
latory mechanisms and biological functions of hTERT
alternative splicing are still uncertain. Our results also
suggest that G-quadruplex stabilizer CX-5461 can
regulate the splicing patterns of hTERT and inhibit tel-
omerase activity in GBM cells. In addition, CX-5461 has
cytotoxicity to GBM cells and can cause telomere DNA
damage response, induce G2/M arrest and cell apoptosis.
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